CHCWM – Cancer & Hematology Centers of West Michigan

Cardiff Oncology CRDF-01E (EAP)

An Expanded Access Program of Onvansertib in Combination with FOLFIRI and Bevacizumab for the Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC)